What is Artelo Biosciences Inc's earnings per share (EPS)?

Artelo Biosciences Inc (ARTL) reported diluted earnings per share of $-37.75 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Artelo Biosciences Inc Financials

ARTL

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Artelo Biosciences Inc (ARTL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ARTL FY2025 2026-05-14

Artelo’s filings depict a development-stage enterprise whose recurring cash burn is increasingly bridged by external financing, not internal resources.

Across the last three annual periods, operating cash burn barely changed, hovering around $8.2M to $8.5M despite shifts inside the expense mix. At the same time, cash on hand fell to $600K and equity turned to -$1.3M, which implies financing is replacing depleted capital rather than a leaner cost base doing the work.

The latest year was a short-term liquidity squeeze: current assets were $695K versus current liabilities of $4.0M. Financing inflow of $6.9M still left ending cash at only $600K, so fresh capital appears to have funded day-to-day continuity more than balance-sheet repair.

The expense profile still reads like a clinical-development platform, but not a research-only one: R&D was $5.4M while SG&A was $6.0M. That balance matters because operating cash outflow of $8.5M remained relatively close to the operating loss of $11.4M, so the reported losses are broadly showing up in cash rather than being softened by working-capital timing.

Financial Health Signals

Financial Profile 15/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Artelo Biosciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Artelo Biosciences Inc carries a low D/E ratio of -3.20, meaning only $-3.20 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Artelo Biosciences Inc's current ratio of 0.17 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak

1/9

Artelo Biosciences Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.66x

For every $1 of reported earnings, Artelo Biosciences Inc generates $0.66 in operating cash flow (-$8.5M OCF vs -$12.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-58.8x

Artelo Biosciences Inc earns $-58.8 in operating income for every $1 of interest expense (-$11.4M vs $194K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$12.9M

YoY-31.1%

Artelo Biosciences Inc reported -$12.9M in net income in fiscal year 2025. This represents a decrease of 31.1% from the prior year.

EPS (Diluted)

$-37.75

Artelo Biosciences Inc earned $-37.75 per diluted share (EPS) in fiscal year 2025. This represents an increase of 31.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$600K

YoY-74.3%

5Y CAGR-32.9%

10Y CAGR+44.9%

Artelo Biosciences Inc held $600K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

673,008

Artelo Biosciences Inc had 673,008 shares outstanding in fiscal year 2025. This represents an increase of 255.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$5.4M

YoY-9.5%

5Y CAGR+37.8%

Artelo Biosciences Inc invested $5.4M in research and development in fiscal year 2025. This represents a decrease of 9.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ARTL Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.4M-9.5%	$6.0M+5.2%	$5.7M+31.7%	$4.3M+14.3%	$3.8M+246.5%	$1.1M
SG&A Expenses	$6.0M+45.3%	$4.1M-2.8%	$4.2M-29.0%	$6.0M+5.9%	$5.6M+491.5%	$952K
Operating Income	-$11.4M-12.8%	-$10.1M-1.8%	-$9.9M+3.5%	-$10.3M-9.2%	-$9.4M-193.4%	-$3.2M
Interest Expense	$194K	$0	$0-100.0%	$5K	$0	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$12.9M-31.1%	-$9.8M-5.8%	-$9.3M+7.9%	-$10.1M-7.2%	-$9.4M-333.1%	-$2.2M
EPS (Diluted)	$-37.75	$-54.89-192.0%	$-18.80	N/A	N/A	$-1.46

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$773K	N/A	$1.3M-31.9%	$1.9M+35.2%	$1.4M	N/A	$325K-80.7%	$1.7M
SG&A Expenses	$1.9M	N/A	$1.8M+41.8%	$1.3M+28.5%	$995K	N/A	$870K+5.2%	$827K
Operating Income	-$2.7M	N/A	-$3.1M+1.9%	-$3.1M-32.4%	-$2.4M	N/A	-$1.2M+52.4%	-$2.5M
Interest Expense	$100K	N/A	$111K+54.2%	$72K	$0	N/A	$0	$0
Income Tax	N/A	N/A	$0	$0	$0	N/A	$0	$0
Net Income	-$3.0M	N/A	-$3.1M+3.1%	-$3.2M-35.8%	-$2.4M	N/A	-$1.1M+53.5%	-$2.4M
EPS (Diluted)	$-4.00	N/A	$-3.97+29.2%	$-5.61+55.3%	$-12.55	N/A	$-2.10+53.5%	$-4.52

ARTL Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY19
Total Assets	$2.8M-40.4%	$4.7M-64.0%	$13.0M-36.1%	$20.4M-27.7%	$28.3M+335.8%	$6.5M
Current Assets	$695K-72.8%	$2.6M-76.7%	$11.0M-40.1%	$18.3M-25.5%	$24.6M+453.9%	$4.4M
Cash & Equivalents	$600K-74.3%	$2.3M-16.9%	$2.8M-59.1%	$6.9M-43.4%	$12.2M+174.9%	$4.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.1M+121.2%	$1.8M+42.6%	$1.3M+26.4%	$1.0M-5.8%	$1.1M+6.0%	$1.0M
Current Liabilities	$4.0M+128.2%	$1.8M+37.3%	$1.3M+29.4%	$998K-2.8%	$1.0M+0.5%	$1.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.3M-144.5%	$2.9M-75.7%	$11.8M-39.4%	$19.4M-28.6%	$27.2M+397.6%	$5.5M
Retained Earnings	-$63.0M-25.7%	-$50.1M-24.4%	-$40.3M-29.9%	-$31.0M-48.2%	-$20.9M-335.2%	-$4.8M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$12.5M+346.9%	$2.8M-34.4%	$4.3M-2.1%	$4.4M+24.0%	$3.5M-25.2%	$4.7M-34.2%	$7.1M-14.3%	$8.3M
Current Assets	$10.4M+1399.4%	$695K-62.0%	$1.8M-18.2%	$2.2M+61.6%	$1.4M-46.0%	$2.6M-48.7%	$5.0M-19.2%	$6.2M
Cash & Equivalents	$10.3M+1612.2%	$600K-65.1%	$1.7M-16.7%	$2.1M+176.9%	$746K-68.1%	$2.3M-46.3%	$4.4M+394.6%	$881K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.8M+43.5%	$4.1M-16.9%	$4.9M-15.0%	$5.8M+101.3%	$2.9M+55.5%	$1.8M+137.5%	$775K-24.5%	$1.0M
Current Liabilities	$5.8M+44.1%	$4.0M-16.8%	$4.9M-14.9%	$5.7M+103.7%	$2.8M+58.2%	$1.8M+154.2%	$697K-25.9%	$940K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.7M+624.5%	-$1.3M-100.9%	-$633K+55.0%	-$1.4M-315.6%	$652K-77.2%	$2.9M-55.1%	$6.4M-12.9%	$7.3M
Retained Earnings	-$66.0M-4.7%	-$63.0M-7.1%	-$58.8M-5.6%	-$55.7M-6.1%	-$52.5M-4.7%	-$50.1M-8.1%	-$46.4M-2.5%	-$45.2M

ARTL Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY19
Operating Cash Flow	-$8.5M-2.0%	-$8.3M-1.7%	-$8.2M-2.5%	-$8.0M-30.4%	-$6.1M-119.9%	-$2.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$62K-100.8%	$7.8M+121.5%	$3.5M+18.6%	$3.0M+186.0%	-$3.4M-129.2%	-$1.5M
Financing Cash Flow	$6.9M+6031.3%	$112K-80.2%	$567K	$0-100.0%	$14.1M+68.5%	$8.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$1.2M+59.1%	-$2.9M+16.8%	-$3.5M-580.5%	-$514K+67.8%	-$1.6M+37.8%	-$2.6M-229.9%	-$778K+62.3%	-$2.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$188K+175.2%	-$250K	$0	$0-100.0%	$500K-88.2%	$4.3M+142.9%	$1.8M
Financing Cash Flow	$10.9M+575.8%	$1.6M-53.3%	$3.4M+89.6%	$1.8M	$0-100.0%	$57K	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ARTL Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-343.9%-264.9pp	-79.0%-27.1pp	-52.0%-17.3pp	-34.6%+5.1pp	-39.8%
Return on Assets	-459.8%-250.7pp	-209.1%-137.9pp	-71.2%-21.9pp	-49.4%-16.1pp	-33.3%+0.2pp	-33.5%
Current Ratio	0.17-1.3	1.44-7.1	8.51-9.9	18.36-5.6	23.96+19.6	4.35
Debt-to-Equity	-3.20-3.8	0.64+0.5	0.11+0.1	0.05+0.0	0.04-0.1	0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-44.3%	N/A	N/A	N/A	-363.8%	N/A	-17.8%+15.5pp	-33.3%
Return on Assets	-23.6%	N/A	-73.1%+0.8pp	-73.9%-6.5pp	-67.5%	N/A	-15.9%+13.4pp	-29.2%
Current Ratio	1.79+1.6	0.17-0.2	0.38-0.0	0.39-0.1	0.49-1.0	1.44-5.7	7.15+0.6	6.56
Debt-to-Equity	0.88+4.1	-3.20+4.5	-7.74-3.6	-4.10-8.5	4.39+3.7	0.64+0.5	0.12-0.0	0.14
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.17), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Silo Pharma Inc SILO

$6.1M

TNF Pharmaceuticals TNFA

$9.6M

CERo Therapeutics CERO

$177K

Adial Pharmaceuticals Inc ADIL

$4.9M

Hcw Biologics Inc. HCWB

$17.4M

Frequently Asked Questions

Is Artelo Biosciences Inc profitable?

No, Artelo Biosciences Inc (ARTL) reported a net income of -$12.9M in fiscal year 2025.

What is Artelo Biosciences Inc's operating cash flow?

Artelo Biosciences Inc (ARTL) generated -$8.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Artelo Biosciences Inc's total assets?

Artelo Biosciences Inc (ARTL) had $2.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Artelo Biosciences Inc spend on research and development?

Artelo Biosciences Inc (ARTL) invested $5.4M in research and development during fiscal year 2025.

How many shares does Artelo Biosciences Inc have outstanding?

Artelo Biosciences Inc (ARTL) had 673,008 shares outstanding as of fiscal year 2025.

What is Artelo Biosciences Inc's current ratio?

Artelo Biosciences Inc (ARTL) had a current ratio of 0.17 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Artelo Biosciences Inc's debt-to-equity ratio?

Artelo Biosciences Inc (ARTL) had a debt-to-equity ratio of -3.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Artelo Biosciences Inc's return on assets (ROA)?

Artelo Biosciences Inc (ARTL) had a return on assets of -459.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Artelo Biosciences Inc's cash runway?

Based on fiscal year 2025 data, Artelo Biosciences Inc (ARTL) had $600K in cash against an annual operating cash burn of $8.5M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Artelo Biosciences Inc's debt-to-equity ratio negative or unusual?

Artelo Biosciences Inc (ARTL) has negative shareholder equity of -$1.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Artelo Biosciences Inc's Piotroski F-Score?

Artelo Biosciences Inc (ARTL) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Artelo Biosciences Inc's earnings high quality?

Artelo Biosciences Inc (ARTL) has an earnings quality ratio of 0.66x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Artelo Biosciences Inc cover its interest payments?

Artelo Biosciences Inc (ARTL) has an interest coverage ratio of -58.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Artelo Biosciences Inc?

Artelo Biosciences Inc (ARTL) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.